Gossamer Bio Holds Special Stockholder Meeting

• Gossamer Bio shareholders approved potential common stock issuance at the October 27, 2026, special meeting.
• The authorization covers issuance exceeding 20% of common shares outstanding immediately before the initial closing under the August 20, 2026, Purchase Agreement.
• Covered shares include those issuable through Pre-Funded Warrants, FDA Approval Warrants and conversion of Series A-1, A-2 and A-3 Preferred Stock.
• The adjournment proposal was not put to a vote because shareholders approved the share issuance proposal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gossamer Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001728117-26-000109), on October 28, 2026, and is solely responsible for the information contained therein.